[go: up one dir, main page]

WO2012112757A3 - Compositions and improved soft tissue replacement methods - Google Patents

Compositions and improved soft tissue replacement methods Download PDF

Info

Publication number
WO2012112757A3
WO2012112757A3 PCT/US2012/025412 US2012025412W WO2012112757A3 WO 2012112757 A3 WO2012112757 A3 WO 2012112757A3 US 2012025412 W US2012025412 W US 2012025412W WO 2012112757 A3 WO2012112757 A3 WO 2012112757A3
Authority
WO
WIPO (PCT)
Prior art keywords
soft tissue
compositions
tissue replacement
replacement methods
improved soft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/025412
Other languages
French (fr)
Other versions
WO2012112757A2 (en
Inventor
Dennis E. Van Epps
Guang-Liang Jiang
Wha-Bin Im
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/193,744 external-priority patent/US8697056B2/en
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to AU2012217630A priority Critical patent/AU2012217630A1/en
Priority to EP12708198.2A priority patent/EP2675491A2/en
Priority to BR112013021035A priority patent/BR112013021035A2/en
Priority to CA2827615A priority patent/CA2827615A1/en
Publication of WO2012112757A2 publication Critical patent/WO2012112757A2/en
Anticipated expiration legal-status Critical
Publication of WO2012112757A3 publication Critical patent/WO2012112757A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3666—Epithelial tissues other than skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3869—Epithelial tissues other than skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)
  • Sanitary Thin Papers (AREA)

Abstract

The specification discloses compositions and methods for treating a soft tissue defect of an individual.
PCT/US2012/025412 2011-02-17 2012-02-16 Compositions and improved soft tissue replacement methods Ceased WO2012112757A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2012217630A AU2012217630A1 (en) 2011-02-17 2012-02-16 Compositions and improved soft tissue replacement methods
EP12708198.2A EP2675491A2 (en) 2011-02-17 2012-02-16 Compositions and improved soft tissue replacement methods
BR112013021035A BR112013021035A2 (en) 2011-02-17 2012-02-16 improved soft tissue replacement compositions and methods
CA2827615A CA2827615A1 (en) 2011-02-17 2012-02-16 Compositions and improved soft tissue replacement methods

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161444078P 2011-02-17 2011-02-17
US61/444,078 2011-02-17
US13/193,744 2011-07-29
US13/193,744 US8697056B2 (en) 2010-08-19 2011-07-29 Compositions and soft tissue replacement methods

Publications (2)

Publication Number Publication Date
WO2012112757A2 WO2012112757A2 (en) 2012-08-23
WO2012112757A3 true WO2012112757A3 (en) 2014-01-09

Family

ID=46673171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/025412 Ceased WO2012112757A2 (en) 2011-02-17 2012-02-16 Compositions and improved soft tissue replacement methods

Country Status (5)

Country Link
EP (1) EP2675491A2 (en)
AU (1) AU2012217630A1 (en)
BR (1) BR112013021035A2 (en)
CA (1) CA2827615A1 (en)
WO (1) WO2012112757A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
EP2814526B1 (en) * 2012-02-16 2016-11-02 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814510A1 (en) * 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
CN115209926B (en) * 2020-03-25 2024-05-14 学校法人福冈大学 Formulations for use in intraocular lens stripping
CN114748682A (en) * 2022-04-26 2022-07-15 深圳湾实验室 Composition for preparing burn wound dressing and preparation and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060069018A1 (en) * 2002-10-10 2006-03-30 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters
WO2008063569A1 (en) * 2006-11-16 2008-05-29 Coapt Systems, Inc. Co-mixed human fat and gel suspension implant material
WO2010026299A1 (en) * 2008-09-08 2010-03-11 Timo Ylikomi Methods and means for soft tissue engineering
WO2012024072A1 (en) * 2010-08-19 2012-02-23 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6199076B1 (en) 1996-10-02 2001-03-06 James Logan Audio program player including a dynamic program selection controller
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US20080299213A2 (en) 1999-11-05 2008-12-04 Donald Kleinsek Augmentation and repair of spincter defects with cells including adipocytic cells
AU2001261465A1 (en) 2000-05-12 2001-11-26 The Regents Of The University Of Michigan Reverse fabrication of porous materials
FR2811996B1 (en) 2000-07-19 2003-08-08 Corneal Ind CROSS-LINKING OF POLYSACCHARIDE (S), PREPARATION OF HYDROGEL (S); POLYSACCHARIDE (S) AND HYDROGEL (S) OBTAINED, THEIR USES
SI1339678T1 (en) 2000-11-27 2007-12-31 Pfizer Prod Inc Ep4 receptor selective agonists in the treatment of osteoporosis
KR100826866B1 (en) 2001-07-23 2008-05-06 오노 야꾸힝 고교 가부시키가이샤 EP4 agonist as an active ingredient
US20040254230A1 (en) 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US7651684B2 (en) 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US6875787B2 (en) 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
AU2003206922A1 (en) 2003-02-19 2004-09-09 Aventis Pharmaceuticals Holdings Inc. Composition and method for intradermal soft tissue augmentation
FR2861734B1 (en) 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
EP1613796B1 (en) 2003-04-10 2017-03-22 Tufts University Concentrated aqueous silk fibroin solution and use thereof
EP1670385B1 (en) 2003-10-01 2013-01-23 University of Washington Novel porous biomaterials
WO2005072701A1 (en) 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
JPWO2006016695A1 (en) 2004-08-10 2008-05-01 小野薬品工業株式会社 Prophylactic and / or therapeutic agent for hyperkalemia containing EP4 agonist
FR2878444B1 (en) 2004-11-30 2008-04-25 Corneal Ind Soc Par Actions Si VISCOELASTIC SOLUTIONS COMPRISING SODIUM HYALURONATE AND HYDROXYPROPYLMETHYLCELLULOSE, PREPARATION AND USES
WO2006137472A1 (en) 2005-06-24 2006-12-28 Taisho Pharmaceutical Co., Ltd. Prostaglandin derivative
US20070036844A1 (en) 2005-08-01 2007-02-15 Ma Peter X Porous materials having multi-size geometries
WO2008092862A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008092860A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008092861A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008103807A2 (en) 2007-02-21 2008-08-28 Cedars-Sinai Medical Center Methods of producing preadipocytes and increasing the proliferation of adult adipose stem/progenitor cells
US8507545B2 (en) 2007-05-08 2013-08-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
GB0810615D0 (en) 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
US8450475B2 (en) 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060069018A1 (en) * 2002-10-10 2006-03-30 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters
WO2008063569A1 (en) * 2006-11-16 2008-05-29 Coapt Systems, Inc. Co-mixed human fat and gel suspension implant material
WO2010026299A1 (en) * 2008-09-08 2010-03-11 Timo Ylikomi Methods and means for soft tissue engineering
WO2012024072A1 (en) * 2010-08-19 2012-02-23 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAUER-KREISEL P ET AL: "Cell-delivery therapeutics for adipose tissue regeneration", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 62, no. 7-8, 15 June 2010 (2010-06-15), pages 798 - 813, XP027473661, ISSN: 0169-409X, [retrieved on 20100413], DOI: 10.1016/J.ADDR.2010.04.003 *
HEMMRICH ET AL: "Autologous In Vivo Adipose Tissue Engineering in Hyaluronan-Based Gels-A Pilot Study", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 144, no. 1, 11 December 2007 (2007-12-11), pages 82 - 88, XP022385921, ISSN: 0022-4804, DOI: 10.1016/J.JSS.2007.03.017 *

Also Published As

Publication number Publication date
WO2012112757A2 (en) 2012-08-23
EP2675491A2 (en) 2013-12-25
BR112013021035A2 (en) 2016-10-11
CA2827615A1 (en) 2012-08-23
AU2012217630A1 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
EP3285688A4 (en) Corneal implants
WO2012149472A9 (en) Methods, compositions, and kits for treating and preventing neurological conditions
EP2531138A4 (en) INTRAOCULAR IMPLANTS, AND KITS AND ASSOCIATED METHODS
EP2663653A2 (en) Methods for diagnosing and treating eye-length related disorders
EP2739237A4 (en) Surgical instrument and control method thereof
IL229257A0 (en) Compositions and methods for treating retinal diseases
HK1198689A1 (en) Antibody formulations and methods
PT2689743T (en) Drill for implant surgery
GB201305198D0 (en) Kits, components and methods for tissue reconstruction
EP2771397A4 (en) Silica-filled rubber composition and method for making the same
WO2013023151A3 (en) Compositions and methods for treating celiac sprue disease
PL2681280T3 (en) Biomaterial, method for making the biomaterial and uses of the same
EP2903537A4 (en) Suture for soft tissue repair
WO2012097272A8 (en) Stable hydrogel compositions including additives
GB2505800B (en) Valve body arrangement and method for manufacture thereof as well as valve having the valve body arrangement
WO2013038269A3 (en) Apparatus and methods for treating sugarcane stem cuttings
EP2732068B8 (en) Method for improving the wear resistance of dyed surgical instruments
EP3016516A4 (en) Soft tissue implant
WO2012112757A3 (en) Compositions and improved soft tissue replacement methods
WO2011097577A9 (en) Compositions and methods for treating or preventing retinal degeneration
WO2012078746A9 (en) Compositions and methods for mobilizing stem cells
WO2013105997A3 (en) Compositions and improved soft tissue replacement methods
WO2013003465A9 (en) Methods and compositions for treating skin
WO2013009678A3 (en) Compositions and methods for the treatment of norovirus infection
HK40032812B (en) Dental implant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12708198

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2827615

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2012217630

Country of ref document: AU

Date of ref document: 20120216

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012708198

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013021035

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013021035

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130816